Sandoz US News and Activities

Sandoz US is owned by Sandoz.

Sandoz is one of the...

• Forbes Global 2000 (#1319);
• TOB Iconic 10,000.

Sandoz is a company listed under the stock ticker SDZNY (DE).

Sandoz has a direct presence in 17 countries.

Sandoz has 18 subsidiaries including Lek, Sandoz Asia and Sandoz Austria.

View the org chart displaying its 19 main executives

Most searched biographies at Sandoz US

• Keren Haruvi, President
• Enrique Linero, Mexico, Andean Region, Central America and the Car...
• Mohammed Obeidat, Vice President and Chief Financial Officer

Popular executive movements at Sandoz US

• Enrique Linero, who was General Manager of Mexico, Central America and Caribbean, is promoted to Mexico, Andean Region, Central America and the Caribbean  (posted on May 11 2026).

Popular executive movements at Sandoz

• Armin Metzger will join the company as President of Biosimilars Development, Manufacturing and Supply on Apr. 1, 2026  (posted on March 27 2026).
• Sidita Sulejmani, who was Head of HR Strategy and Portfolio Management, is promoted to Head of Human Resources Development  (posted on December 21 2025).

Create your alert
to follow the executive moves at Sandoz US.

Sandoz has 1,913 competitors including Sanofi (France), Eli Lilly (United States (USA)) and Moderna (United States (USA)).

Popular M&A news in Pharmaceuticals

• Contraline has just announced a $93 Million fundraising (posted on June 3 2026).
• Hims & Hers has acquired Eucalyptus (posted on June 2 2026).
• Apotex has filed its IPO. Its stock ticker will be TSX. (posted on June 2 2026).

Popular contacts in Pharmaceuticals

• Joaquin Duato - Chief Executive Officer and Chairman of the Board at Johnson & Johnson
• Richard Saynor - Chief Executive Officer at Sandoz
• Robert Ford - Chief Executive Officer and Chairman of the Board at Abbott

Learn more about the Pharmaceuticals industry

Press releases by Sandoz US

• FDA approves Tyruko® (natalizumab-sztn), the first and only FDA-approved biosimilar for relapsing forms of multiple sclerosis | Sandoz US
• Sandoz AG expands reach of adalimumab biosimilar in US through commercialization agreement with Cordavis | Sandoz US
• Sandoz receives FDA approval for Tyruko® (natalizumab-sztn), first and only FDA-approved biosimilar for relapsing forms of multiple sclerosis | Sandoz US
• Hyrimoz® (adalimumab-adaz) high-concentration formulation now available in the US | Sandoz US
• Sandoz to launch Hyrimoz® (adalimumab-adaz) high-concentration formulation, marking Sandoz entrance into US immunology space | Sandoz US
• Sandoz introduces Act4Biosimilars Action Plan to accelerate patient access to biosimilar medicines | Sandoz US
• Sandoz introduces Act4Biosimilars Action Plan to accelerate patient access to biosimilar medicines | Sandoz US
• Sandoz receives US FDA approval for biosimilar Hyrimoz® (adalimumab-adaz) high-concentration formulation | Sandoz US
• Engaging with Critical Stakeholders at the 2023 National Health Council’s Leadership Conference | Sandoz US
• Sandoz Biologics License Application for proposed biosimilar denosumab accepted by US FDA | Sandoz US
• View more press releases Close

Social media about Sandoz US

• Sandoz US on Wikipedia, Google News & Yahoo Finance
• Sandoz US on LinkedIn, X (Twitter) & YouTube